About
ANTARA®

For the treatment of primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia as adjunctive therapy to diet

In patients with low HDL-C and high TG, the addition of fenofibrate lowered cardiovascular-related events by approximately 30%1,2

  • Although the addition of fenofibrate did not reduce CHD events and CHD-related mortality in the entire study population, patients with low HDL-C (<34 mg/dL) and high TG levels (>204 mg/dL) at baseline did experience a clinical benefit1
  • CHD-related events or death were reduced by approximately 30% in this subset of patients1
  • The value in this group was 0.057, which falls short of being statistically significant1,2

Important limitations of use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.

ACCORD Sub-study1

Patients Experiencing MI, Stroke, or Cardiovascular-Related Death2

References
  1. ACCORD Study Group. Effects of combination lipid therapy in Type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574.
  2. Ginsberg HN. The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial: What we learn from subgroup analyses. Diabetes Care. 2011;34(Suppl. 2): S106-108.